Search
PI-166
go.drugbank.com/drugs/DB05859ExperimentalPI-166 is a small organic compound with specific avidity to liver cancer cells.
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalMyasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, a...
Pine needle oil (pinus mugo)
go.drugbank.com/drugs/DB11276ApprovedIt is present in aromatherapeutic agents as a massage oil or fragrance and may also be used as a disinfectant, lubricant, sanitizer, antimicrobial, insecticide and organic herbicide.
ISP-001
go.drugbank.com/drugs/DB18501InvestigationalISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and delivery of alpha-L-iduronidase.
Ocaratuzumab
go.drugbank.com/drugs/DB17359InvestigationalOcaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.
Synonyms: Immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1))TOL2
go.drugbank.com/drugs/DB17918ExperimentalTOL2 is a modified form of the acetylcholine receptor being investigated for the treatment of myasthenia gravis.[A260117]
Pyrrolidone
go.drugbank.com/drugs/DB19152ExperimentalPyrrolidone is under investigation in clinical trial NCT05444998 (Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for Her2+breast Cancer).
Cannabidiolic acid
go.drugbank.com/drugs/DB19261InvestigationalCannabidiolic acid is under investigation in clinical trial NCT04103814 (Effect of Topical CBD Cream for Degenerative Hallux Disorders).
Synonyms: CBD-AAmrubicin
go.drugbank.com/drugs/DB06263InvestigationalAmrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.
Iclaprim
go.drugbank.com/drugs/DB06358InvestigationalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use